Featured Articles

1. What If The U.S. Government Stopped Funding Biotech? 3/23/2026

   It sets off a real tension – ideological, economic, even personal. But what would happen if the U.S. government cut direct financial support for “biotechnology research,” leaving it entirely to investors, private and public markets, and bigger pharma? "Our industry’s mind-meld says with no government largesse our biotech industry collapses," writes Chief Editor Louis Garguilo. It's an "outlandish hypothetical," but he asks for a few minutes to go through this. And he has help in making his case.

2. The Human Variable: The Leadership Risk Biotech Governance Still Ignores 3/12/2026

   The mental faculties a biotech CEO needs most are the first to degrade under chronic pressure. This is not a character issue, it's physiological, writes Maria Bostock.

3. Building Strategic Partnerships Between IP Law Firms And Biopharma 3/4/2026

   Patent attorney Eric M. Brusca, Ph.D., explains how biopharmaceutical companies and their IP law firms can cultivate relationships that drive meaningful business value.

4. Where Are They Now? Life Science Cares 2/27/2026

   Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty.

5. Life Sciences Hubs Creating More Opportunity For Startups And Investors 2/26/2026

   Life sciences hubs beyond Boston and the Bay Area are giving startups new opportunities to grow and scale their businesses, writes Mike Carnes at NCBiotech.

6. How Strategic Collaborations Can Accelerate Innovation And Create Value 2/24/2026

   Platform biotechs should aim for partnerships that compound value over time, beyond a simple funding mechanism, writes Unnatural Products CEO Cameron Pye, Ph.D.  

7. Time Is Lives: How Collaboration And Urgency Are Rewriting The Future Of Rare Disease 2/19/2026

   The inflection point has arrived, says Rob Freishtat, MD, MPH. Understand how collaboration will rewrite how we think of rare disease clinical research.

8. Activate These Three Levers To Create A More Effective Workforce 2/13/2026

   A convergence of market forces will push life sciences employers to rethink their workforce strategies and reimagine how work gets done, writes Ruby van den Hoff.

9. Why Human Leadership Matters More Than Ever In The AI Era 2/10/2026

   In the AI era, thriving life sciences organizations will differentiate themselves based on their ability to combine AI's power with distinctly human capabilities, writes Christine Ann Miller.

10. Policy Matters: The Reauthorized Rare Pediatric Disease Voucher Program 2/5/2026

    Congress finally reauthorized the Rare Pediatric Disease Priority Review Voucher program, after it expired in 2024. That matters a lot to patients and drug developers, writes George Magrath, M.D.